MedTrace Logo

QTX3034 in Patients With KRAS G12D Mutation

NCT06227377 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2026-04-27

No results posted yet for this study

Summary

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

Conditions

Interventions

DRUG

QTX3034

QTX3034 will be administered at protocol defined dose

COMBINATION_PRODUCT

Cetuximab

Cetuximab will be administered at protocol defined dose.

Sponsors & Collaborators

  • Quanta Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-05
Primary Completion
2027-04-01
Completion
2027-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06227377 on ClinicalTrials.gov